{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:17:25Z","timestamp":1787991445887,"version":"build-2784847793"},"reference-count":44,"publisher":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:p>Background: DKD is a leading cause of end-stage renal disease with limited therapeutic options. Objectives: This study evaluated the effects of Xiaoshen Formula (XSF) on glucose\/lipid metabolism and renal injury in a DKD model of mice and preliminarily explored its mechanisms involving the JAK\/STAT pathway and PPAR?. Methods: Diabetes and early-stage DKD were established in KK-Ay mice. Successfully modeled mice were randomly assigned to preventive or therapeutic administration groups; C57BL\/6J mice served as blank controls. Biochemical parameters, kidney index and renal histopathology (hematoxylin-eosin staining and transmission electron microscopy) were assessed. Renal protein expression was determined by Western blot. Results: Compared with blank controls, model mice exhibited increased body weight, polydipsia, polyphagia, disrupted glucose\/lipid metabolism and renal injury, confirming successful modeling. Irbesartan reduced fasting blood glucose, kidney weight, organ index and renal injury. XSF-H significantly improved glucose\/lipid metabolism, reduced food\/water intake and kidney weight\/organ index and alleviated renal injury, with overall efficacy ranking: high-dose &gt; therapeutic &gt; low-dose. Western blot showed lower levels of JAK2, p-STAT-6, TGF-?1, and FN, and higher levels of PPAR? in the Irbesartan and XSF groups compared with the model group. Conclusion: This study provides experimental evidence that XSF may delay early DKD progression. XSF ameliorates fasting blood glucose, stabilizes body weight, improves glucose\/lipid metabolism and attenuates renal injury and no obvious hepatorenal toxicity under limited conditions. Findings suggest that XSF delays DKD progression may be associated with modulation of the JAK\/STAT signaling pathway and inhibition of renal fibrosis.<\/jats:p>","DOI":"10.36721\/pjps.2026.39.11.303.1","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T06:40:39Z","timestamp":1784961639000},"source":"Crossref","is-referenced-by-count":0,"title":["Xiaoshen formula delays progression of diabetic kidney disease and improves glucose and lipid metabolism: Association with the JAK\/STAT pathway"],"prefix":"10.36721","author":[{"given":"Han","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22735","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Kidney disease: Improving global outcomes (KDIGO) CKD Work Group, 2024. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int, 105(4S): S117-S314.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Ali AA, Aljumayi H, Aljutaily T, Alfheeaid HA, Al-Zunaidy NBA, Mohamed Ahmed IA, Mohammed BM and Khalil NA (2025). The hypolipemic properties of kaempferol presented in microwaved cooked broccoli between hyperlipidemic rat models. Food Sci. Nutr., 13: e70556.","DOI":"10.1002\/fsn3.70556"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N and Defronzo RA (2007). Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia, 50: 1723-31.","DOI":"10.1007\/s00125-007-0698-9"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Banji D, Alqahtani SS, Banji OJF, Machanchery S and Shoaib A (2021). Calming the inflammatory storm in severe COVID-19 infections: Role of biologics- A narrative review. Saudi Pharm J, 29: 213-222.","DOI":"10.1016\/j.jsps.2021.01.005"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Cao Y, Wang J, Jiang S, Lyu M, Zhao F, Liu J, Wang M, Pei X, Zhai W, Feng X, Feng S, Han M, Xu Y and Jiang E (2023). JAK1\/2 inhibitor ruxolitinib promotes the expansion and suppressive action of polymorphonuclear myeloid-derived suppressor cells via the JAK\/STAT and ROS-MAPK\/NF-\u03baB signalling pathways in acute graft-versus-host disease. Clin Transl Immunology, 12: e1441.","DOI":"10.1002\/cti2.1441"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Du X, Wang X, Cui K, Chen Y, Zhang C, Yao K, Hao Y and Chen Y (2021). Tanshinone IIA and astragaloside IV inhibit miR-223\/JAK2\/STAT1 signalling pathway to alleviate lipopolysaccharide-induced damage in nucleus pulposus cells. Dis Markers, 2021: 6554480.","DOI":"10.1155\/2021\/6554480"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH and Kanik KS (2012). Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med, 367: 495-507.","DOI":"10.1056\/NEJMoa1109071"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Francis A, Harhay MN, Ong ACM, Tummalapalli SL, Ortiz A, Fogo AB, Fliser D, Roy-Chaudhury P, Fontana M, Nangaku M, Wanner C, Malik C, Hradsky A, Adu D, Bavanandan S, Cusumano A, Sola L, Ulasi I and Jha V (2024). Chronic kidney disease and the global public health agenda: An international consensus. Nat Rev Nephrol, 20: 473-485.","DOI":"10.1038\/s41581-024-00820-6"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Fu Y, Zhang X, Xu R and Lv B (2025). Fisetin-mediated PPAR-\u03b3 upregulation: A novel therapeutic approach for corpus cavernosum smooth-muscle-cell apoptosis and restoration of erectile function after cavernous nerve injury. Transl Androl Urol, 14: 1429-1443.","DOI":"10.21037\/tau-2025-63"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Gao C, Aqie K, Zhu J, Chen G, Xu L, Jiang L and Xu Y (2014). MG132 ameliorates kidney lesions by inhibiting the degradation of Smad7 in streptozotocin-induced diabetic nephropathy. J Diabetes Res, 2014: 918396.","DOI":"10.1155\/2014\/918396"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Genitsaridi I, Salpea P, Salim A, Sajjadi SF, Tomic D, James S, Thirunavukkarasu S, Issaka A, Chen L, Basit A, Luk AOY, Ma RCW, Mbanya JC, Ramachandran A, Wild SH, Duncan BB, Boyko EJ and Magliano DJ (2025). 11th edition of the IDF Diabetes Atlas: Global, regional and national diabetes prevalence estimates for 2024 and projections for 2050. Lancet Diabetes Endocrinol.","DOI":"10.2139\/ssrn.5327047"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Guo M, Ni L and Wu X (2025). Natural products as potential therapeutic candidates for diabetic kidney disease: Molecular mechanisms, translational challenges and future prospects. Int J Mol Sci, 26(23): 11637.","DOI":"10.3390\/ijms262311637"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Hu X, Li J, Fu M, Zhao X and Wang W (2021). The JAK\/STAT signaling pathway: From bench to clinic. Signal Transduct Target Ther, 6: 402.","DOI":"10.1038\/s41392-021-00791-1"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Hu Y, Liu S, Liu W, Zhang Z, Liu Y, Li S, Sun D, Zhang G and Fang J (2022). Potential molecular mechanism of yishen capsule in the treatment of diabetic nephropathy based on network pharmacology and molecular docking. Diabetes Metab Syndr Obes, 15: 943-962.","DOI":"10.2147\/DMSO.S350062"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Jayaraman S, Devarajan N, Rajagopal P, Babu S, Ganesan SK, Veeraraghavan VP, Palanisamy CP, Cui B, Periyasamy V and Chandrasekar K (2021). \u03b2-Sitosterol circumvents obesity induced inflammation and insulin resistance by down-regulating IKK\u03b2\/NF-\u03baB and JNK signaling pathway in adipocytes of type 2 diabetic rats. Molecules, 26(7): 2101.","DOI":"10.3390\/molecules26072101"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Jiao B, An C, Du H, Tran M, Wang P, Zhou D and Wang Y (2021). STAT6 deficiency attenuates myeloid fibroblast activation and macrophage polarization in experimental folic acid nephropathy. Cells, 10(11): 3057.","DOI":"10.3390\/cells10113057"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Jin T, Du Y, Liu C, Zhao J and Liu T (2025). Advances in ginsenoside treatment for common kidney diseases: Pharmacological evaluation and potential mechanisms. Front Pharmacol, 16: 1702234.","DOI":"10.3389\/fphar.2025.1702234"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Kielian T and Drew PD (2003). Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation. J Neurosci Res, 71: 315-25.","DOI":"10.1002\/jnr.10501"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Li Y, Li Y, Chen N, Feng L, Gao J, Zeng N, He Z and Gong Q (2022). Icariside II exerts anti-type 2 diabetic effect by targeting PPAR\u03b1\/\u03b3: Involvement of ROS\/NF-\u03baB\/IRS1 signaling pathway. Antioxidants (Basel), 11(9): 1705.","DOI":"10.3390\/antiox11091705"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Liao X, Jiang Y, Dai Q, Yu Y, Zhang Y, Hu G, Meng J, Xie Y, Peng Z and Tao L (2021). Fluorofenidone attenuates renal fibrosis by inhibiting the mtROS-NLRP3 pathway in a murine model of folic acid nephropathy. Biochem Biophys Res Commun, 534: 694-701.","DOI":"10.1016\/j.bbrc.2020.11.017"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Lin H, Yang Y, Wang X, Chung M, Zhang L, Cai S, Pan X and Pan Y (2025). Targeting the AGEs-RAGE axis: Pathogenic mechanisms and therapeutic interventions in diabetic wound healing. Front Med (Lausanne), 12: 1667620.","DOI":"10.3389\/fmed.2025.1667620"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Lin SY, Yang CP, Wang YY, Hsiao CW, Chen WY, Liao SL, Lo YL, Chang YH, Hong CJ and Chen CJ (2020). Interleukin-4 improves metabolic abnormalities in leptin-deficient and high-fat diet mice. Int J Mol Sci, 21(12): 4451.","DOI":"10.3390\/ijms21124451"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Liu L, Sun Q, Bao R, Roth M, Zhong B, Lan X, Tian J, He Q, Li D, Sun J, Yang X and Lu S (2016). Specific regulation of PRMT1 expression by PIAS1 and RKIP in BEAS-2B epithelia cells and HFL-1 fibroblasts in lung inflammation. Sci Rep, 6: 21810.","DOI":"10.1038\/srep21810"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Liu X, Jiang L, Zeng H, Chen Y, Wang L, Zhang H and Li W (2024). Circ-0000953 deficiency exacerbates podocyte injury and autophagy disorder by targeting Mir665-3p-Atg4b in diabetic nephropathy. Autophagy, 20(5): 1072-1097.","DOI":"10.1080\/15548627.2023.2286128"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Ma Y, Deng Y, Li N, Dong A, Li H, Chen S, Zhang S and Zhang M (2023). Network pharmacology analysis combined with experimental validation to explore the therapeutic mechanism of Schisandra Chinensis Mixture on diabetic nephropathy. J Ethnopharmacol, 302: 115768.","DOI":"10.1016\/j.jep.2022.115768"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Miao X, Leng X and Zhang Q (2017). The current state of nanoparticle-induced macrophage polarization and reprogramming research. Int J Mol Sci, 18(2): 336.","DOI":"10.3390\/ijms18020336"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Mossahebi-Mohammadi M, Quan M, Zhang JS and Li X (2020). FGF signaling pathway: A key regulator of stem cell pluripotency. Front Cell Dev Biol, 8: 79.","DOI":"10.3389\/fcell.2020.00079"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Oki C, Uno K, Sasase T, Tsutsui T, Sekiguchi K, Yamaguchi A, Mandai K, Shinohara M, Sugimoto M, Maekawa T, Miyajima K and Ohta T (2025). High-fat\/high-sucrose diet-induced renal changes in obese diabetic mice: A comparison with db\/db and KK-Ay mice. J Vet Med Sci, 87: 138-146.","DOI":"10.1292\/jvms.24-0313"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Pan D, Qu Y, Shi C, Xu C, Zhang J, Du H and Chen X (2024). Oleanolic acid and its analogues: Promising therapeutics for kidney disease. Chin Med, 19: 74.","DOI":"10.1186\/s13020-024-00934-w"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Qu Q, Liu SY, Fu B, Zhang Q, Li J, Chen H, Wang X, Liu Y and Sun L (2025). Gingival mesenchymal stem cell-derived exosomal miR-23a-3p targets IL-6R to attenuate autoimmune insulitis: A cell-free therapeutic strategy for type 1 diabetes. Stem Cell Res Ther, 16(1): 633.","DOI":"10.1186\/s13287-025-04744-1"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Rockwood S, Mason D, Lord R, Lamar P, Prozialeck W and Al-Nakkash L (2019). Genistein diet improves body weight, serum glucose and triglyceride levels in both male and female ob\/ob mice. Diabetes Metab Syndr Obes, 12: 2011-2021.","DOI":"10.2147\/DMSO.S216312"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Roh E and Choi KM (2023). Hormonal gut-brain signaling for the treatment of obesity. Int J Mol Sci, 24(4): 3384.","DOI":"10.3390\/ijms24043384"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn EJ, Ichai C, Joannidis M, Soupart A, Zietse R, Haller M, Van Der Veer S, Van Biesen W and Nagler E (2014). Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant, 29(Suppl 2): i1-i39.","DOI":"10.1093\/ndt\/gfu040"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Takasu T, Kakuta H, Sasamata M and Yamagishi S (2006). An angiotensin II (Ang II) type 1 receptor blocker, telmisartan, improves insulin resistance in KK-A(y) diabetic mice. Int J Biomed Sci, 2: 333-6.","DOI":"10.59566\/IJBS.2006.2333"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Tao X, Wu Y, Guo F, Lv L, Zhai X, Shang D, Yu Z, Xiang H and Dong D (2025). Targeted inhibitors of S100A9 alleviate chronic pancreatitis by inhibiting M2 macrophage polarization via the TAOK3-JNK signaling pathway. Front Immunol, 16: 1526813.","DOI":"10.3389\/fimmu.2025.1526813"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Waibel M, Wentworth JM, So M, Couper JJ, Cameron FJ, Macisaac RJ, Atlas G, Gorelik A, Litwak S, Sanz-Villanueva L, Trivedi P, Ahmed S, Martin FJ, Doyle ME, Harbison JE, Hall C, Krishnamurthy B, Colman PG, Harrison LC, Thomas HE and Kay TWH (2023). Baricitinib and \u03b2-cell function in patients with new-onset type 1 diabetes. N Engl J Med, 389: 2140-2150.","DOI":"10.1056\/NEJMoa2306691"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, Dorner T, Cardiel MH, Bruce IN, Gomez E, Carmack T, Delozier AM, Janes JM, Linnik MD, De Bono S, Silk ME and Hoffman RW (2018). Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet, 392: 222-231.","DOI":"10.1016\/S0140-6736(18)31363-1"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Wehbe F, Elliott M and Levin A (2025). CKDs at the crossroads: From failures to future therapies. Kidney Int Rep, 10: 4145-4161.","DOI":"10.1016\/j.ekir.2025.09.050"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Wang G, Zhu X, Liang S, Xu F, Liang D and Zeng C (2025). Optimizing preparation of renal biopsy specimens for TEM: A time-efficient approach to rapid diagnosis of kidney diseases. Ren Fail, 47(1): 2522325.","DOI":"10.1080\/0886022X.2025.2522325"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Xu Z, Yang S, Tan Y, Zhang Q, Wang H, Tao J, Liu Q, Wang Q, Feng W, Li Z, Wang C and Cui L (2025). Inflammation in cardiovascular-kidney-metabolic syndrome: Key roles and underlying mechanisms-a comprehensive review. Mol Cell Biochem, 480: 6039-6075.","DOI":"10.1007\/s11010-025-05379-9"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Yan J, Zhang Z, Yang J, Mitch WE and Wang Y (2015). JAK3\/STAT6 stimulates bone marrow-derived fibroblast activation in renal fibrosis. J Am Soc Nephrol, 26: 3060-71.","DOI":"10.1681\/ASN.2014070717"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, Jia J, Yan T, Liu Y and Lin S (2020). ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3-5: A network meta-analysis of randomised clinical trials. Drugs, 80: 797-811.","DOI":"10.1007\/s40265-020-01290-3"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Zhao W, Liu L, Wang Y, Mao T and Li J (2016). Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-\u03b3 and insulin receptor in a rat model of nonalcoholic fatty liver disease. Exp Ther Med, 11: 183-190.","DOI":"10.3892\/etm.2015.2846"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Zhu M, Wei R, Yuan B, Li S and Hu F (2025). Integrated transcriptomics and network pharmacology reveal the mechanism of poplar-type propolis on the mouse mastitis model. Nutrients, 17(23): 3683.","DOI":"10.3390\/nu17233683"}],"container-title":["Pakistan Journal of Pharmaceutical Sciences"],"original-title":[],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:15:00Z","timestamp":1787991300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pjps.pk\/single-article?id=7909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":44,"URL":"https:\/\/doi.org\/10.36721\/pjps.2026.39.11.303.1","relation":{},"ISSN":["1011-601X","3105-9686"],"issn-type":[{"value":"1011-601X","type":"print"},{"value":"3105-9686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]}}}